Loading…
LivaNova PLC is projected to rise to $103.07 by 2027, a +39% move from its current price of $73.90. LIVN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $72.43 | $73.96 | $75.52 | +0.08% |
| May 30 | $71.87 | $74.02 | $76.23 | +0.16% |
| May 31 | $71.45 | $74.07 | $76.80 | +0.24% |
| Jun 1 | $71.11 | $74.13 | $77.29 | +0.32% |
| Jun 2 | $70.81 | $74.19 | $77.73 | +0.39% |
| Jun 3 | $70.55 | $74.25 | $78.14 | +0.47% |
| Jun 4 | $70.32 | $74.31 | $78.52 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $70.32 | $74.31 | $78.52 | +0.55% |
| Week 2 | $69.11 | $74.72 | $80.78 | +1.11% |
| Week 3 | $68.29 | $75.13 | $82.66 | +1.67% |
| Week 4 | $67.66 | $75.55 | $84.36 | +2.23% |
| Week 5 | $67.15 | $75.96 | $85.93 | +2.79% |
| Week 6 | $66.73 | $76.38 | $87.43 | +3.36% |
| Week 7 | $66.38 | $76.81 | $88.87 | +3.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
LivaNova PLC is a medical technology company that designs, develops, manufactures, markets, and sells products, therapies, and services across a broad set of countries, including the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark, with international reach beyond those markets.
The company operates in two segments: Cardiopulmonary and Neuromodulation. The Neuromodulation segment offers the VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist the implant procedure, and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. It also includes the aura6000 system for treating obstructive sleep apnea, which is in development and clinical testing.
The organization serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and medical institutions, selling devices through direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
LivaNova PLC is trading at $73.83 per share with a market cap of $4.06B and a market rank of 1499.
The stock’s near-term fundamentals show bullish dynamics with a 30-day technical backdrop that supports upside potential. The 30-day range is $64.17 to $84.94, and the sentiment indicator is bullish. The SMA50 sits at $65.22 and the SMA200 at $60.58, with a nearby support level at $57.59 and a resistance at $73.83.
Forecasts illuminate an upside path through 2030 and beyond, with 2026 averaging $73.83 (min $57.59, max $103.26) and 2030 averaging $132.49 (min $101.78, max $184.52). The longer horizon strengthens markedly by 2040 (avg $379.37, min $261.30, max $597.21) and 2050 (avg $703.95, min $446.87, max $1,195.00), with bullish sentiment attached to the years in between.
A major floor 30.8% below — a decisive break under it would weaken the trend.
The nearest floor, 22.1% below — buyers have tended to step in here.
Price is pressing into resistance (2.1% away) — a breakout level to watch.
A major ceiling 17.5% above — clearing it would confirm fresh momentum.
Key LIVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LIVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $74.10 | Sell | $73.90 | Sell |
| MA 10 | $72.98 | Buy | $72.70 | Buy |
| MA 20 | $68.87 | Buy | $70.40 | Buy |
| MA 50 | $65.80 | Buy | $67.31 | Buy |
| MA 100 | $65.34 | Buy | $64.92 | Buy |
| MA 200 | $60.84 | Buy | $60.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.59 | Neutral |
| Stoch RSI (14) | 43.35 | Neutral |
| CCI (20) | 66.77 | Neutral |
| Williams %R (14) | -28.04 | Info |
| MACD (12,26,9) | 0.44 | Buy |
| ROC (12) | 2.84 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 71.96 | Neutral |
| TRIX (15) | 0.51 | Buy |
| Awesome (5,34) | 7.04 | Buy |
| Ultimate (7,14,28) | 72.82 | Sell |
| Momentum (10) | 2.15 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 75.00 | Sell |
| ADX (14) | 23.55 | Buy |
| ATR (14) | 1.41 | Info |
The near-term technical picture is bullish, as reflected by the sentiment and price action. RSI14 is 60, suggesting modest momentum without overbought conditions. The stock trades above the SMA50 of $65.22 and above the SMA200 of $60.58, implying a constructive trend.
The 30-day range runs from $64.17 to $84.94, positioning the current price near the middle of a recent trading window. Key levels include support at $57.59 and resistance at $73.83, framing the near-term path visible within this range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $57.59 | $73.90 | $102.34 | 0% | Neutral | |
| $83.62 | $103.07 | $133.39 | +39% | Bullish | |
| $87.59 | $110.16 | $146.65 | +49% | Bullish | |
| $93.53 | $119.62 | $162.86 | +62% | Bullish | |
| $100.14 | $130.00 | $180.40 | +76% | Bullish | |
| $108.96 | $143.35 | $202.31 | +94% | Bullish | |
| $133.12 | $177.34 | $254.11 | +140% | Bullish | |
| $147.90 | $199.35 | $289.62 | +170% | Bullish | |
| $155.73 | $212.24 | $312.31 | +187% | Bullish | |
| $165.36 | $227.76 | $339.15 | +208% | Bullish | |
| $255.33 | $368.75 | $577.42 | +399% | Bullish | |
| $429.80 | $672.08 | $1,133.71 | +809% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $57.59 | $73.90 | $87.01 | +0.00% |
| June 2026 | $66.78 | $78.03 | $93.04 | +5.59% |
| July 2026 | $67.52 | $79.40 | $95.65 | +1.75% |
| August 2026 | $66.89 | $79.05 | $95.99 | -0.44% |
| September 2026 | $68.04 | $80.74 | $98.69 | +2.14% |
| October 2026 | $69.36 | $82.61 | $101.58 | +2.32% |
| November 2026 | $68.61 | $82.00 | $101.34 | -0.75% |
| December 2026 | $68.73 | $82.40 | $102.34 | +0.49% |
Click any year to see its month-by-month LIVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LIVN could reach as high as $102.34, with a base case around $73.90 and support toward $57.59 — roughly 0% from $73.90. Price action looks broadly range-bound.
Expect LIVN to range from $83.62 to $133.39 through 2027. The $103.07 average target implies a +39% move from current prices. That is up +39% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The LIVN price prediction for 2028 points to an average of $110.16 (low $87.59, high $146.65) — a potential gain of +49% on today's $73.90. Momentum favours further upside here.
In 2029, LIVN is projected to trade between $93.53 and $162.86, averaging $119.62 — a potential gain of +62% from today's $73.90. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
LivaNova PLC's 2030 outlook centres on $130.00, within a $100.14 to $180.40 range. That is up +9% on the projected 2029 average. That marks a +76% change versus current levels. Momentum favours further upside here.
By 2031, LIVN could reach as high as $202.31, with a base case around $143.35 and support toward $108.96 — roughly +94% from $73.90. Buyers look set to stay in control over this stretch.
Expect LIVN to range from $133.12 to $254.11 through 2032. The $177.34 average target implies a +140% move from current prices. That is up +24% on the projected 2031 average. Momentum favours further upside here.
The LIVN price prediction for 2033 points to an average of $199.35 (low $147.90, high $289.62) — a potential gain of +170% on today's $73.90. Buyers look set to stay in control over this stretch.
In 2034, LIVN is projected to trade between $155.73 and $312.31, averaging $212.24 — a potential gain of +187% from today's $73.90. That is up +6% on the projected 2033 average. Momentum favours further upside here.
LivaNova PLC's 2035 outlook centres on $227.76, within a $165.36 to $339.15 range. That is up +7% on the projected 2034 average. That marks a +208% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, LIVN could reach as high as $577.42, with a base case around $368.75 and support toward $255.33 — roughly +399% from $73.90. Momentum favours further upside here.
Expect LIVN to range from $429.80 to $1,133.71 through 2050. The $672.08 average target implies a +809% move from current prices. That is up +82% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LIVN today (≈ 13.5318 LIVN) could be worth
$9,094.5
+$8,094.5 (+809%) by 2050 · US Dollar
Based on the average projected LIVN price of $672.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LIVNwould be worth at today's price.
$1,000 invested in LIVN on May 27, 2025 (≈ 22.716947 LIVN) would be worth
$1,678.78
+$678.78 (+67.9%) today · 1.68× · US Dollar
Based on a LIVN entry price of $44.02 vs. today's $73.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $73.71 | $1,002.58 | +0.3% |
| 1 month ago | $63.41 | $1,165.43 | +16.5% |
| 3 months ago | $71 | $1,040.85 | +4.1% |
| 6 months ago | $63.81 | $1,158.13 | +15.8% |
| 1 year ago | $44.02 | $1,678.78 | +67.9% |
| All time (5.0y) ago | $81.69 | $904.64 | -9.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LIVN forecast.
Our base-case forecast reaches $150.00 around 2032.
Implied market cap at $150.00: $8.24B
Across the multi-year forecast, the outlook remains bullish with progressively higher averages and sizable upside. For 2030, the average price is $132.49 with an ROI of 79.5 and a bullish sentiment, alongside a min of $101.78 and a max of $184.52.
In 2040, the forecast shows an average of $379.37 with an ROI of 413.8, still bullish, with a min of $261.30 and a max of $597.21.
By 2050, the average climbs to $703.95 with an ROI of 853.5, remaining bullish, and a min of $446.87 and a max of $1,195.00.
These figures illustrate strong long-term upside potential, but they are estimates and not guarantees. The projected path reflects bullish sentiment in the later forecast years and should be considered in the context of inherent investment uncertainty.
Tap a question to reveal the answer.
Avg $132.49; Min $101.78; Max $184.52; ROI: 79.5; Sentiment: BULLISH.
Forecasts show bullish sentiment in 2030 and beyond, with rising averages (2030 avg $132.49; 2040 avg $379.37; 2050 avg $703.95). These are estimates and not guarantees.
Yes—the 2050 max is $1,195.00.
Current price: $73.83; Market cap: $4.06B.
Low $64.17; High $84.94.
LivaNova PLC Community Discussion
0Share your LivaNova PLC price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.